| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
NL-103 manufacturers
- NL-103
-
- $1980.00
-
2026-04-20
- CAS:1788896-33-2
- Purity:
- Supply Ability: 10g
|
| Product Name: | NL-103 | | Synonyms: | NL-103;3-Pyridinecarboxamide, N-[4-chloro-3-[(3-chlorobenzoyl)amino]phenyl]-6-[[7-(hydroxyamino)-7-oxoheptyl]amino]- | | CAS: | 1788896-33-2 | | MF: | C26H27Cl2N5O4 | | MW: | 544.43 | | EINECS: | | | Product Categories: | | | Mol File: | 1788896-33-2.mol |  |
| | NL-103 Chemical Properties |
| density | 1.409±0.06 g/cm3(Predicted) | | pka | 9.48±0.20(Predicted) |
| | NL-103 Usage And Synthesis |
| Description | NL-103 is a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. NL-103 comprises structural elements of Hh pathway inhibitor vismodegib, and histone deacetylase (HDAC) inhibitor vorinostat. NL-103 simultaneously and significantly inhibited both HDACs and Hh pathway. Importantly, NL-103 effectively overcame vismodegib resistance induced by Smoothened point mutations. Moreover, NL-103 significantly downregulated the expression of Gli2 which plays an important role in Hh pathway. NL-103 may be a promising compound for clinical development as a more effective Hh pathway inhibitor. | | Uses | NL-103 is an inhibitor of histone deacetylases (HDACs) and Hedgehog, with the IC50 values of 21.3 nM, 57 nM, 74 nM, and 680 nM for HDAC1, HDAC2, HDAC3, and HDAC6, respectively. NL-103 can downregulate the expression of Gli2. NL-103 can be used in anti-cancer research[1]. | | IC 50 | HDAC1: 21.3 nM (IC50); HDAC2: 57 nM (IC50); HDAC3: 74 nM (IC50); HDAC6: 680 nM (IC50) | | References | [1] Zhao J, et al. NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. Pharmacol Res Perspect. 2014 Jun;2(3):e00043. DOI:10.1002/prp2.43 |
| | NL-103 Preparation Products And Raw materials |
|